Shell Asset Management CO Gilead Sciences, Inc. Transaction History

Shell Asset Management CO

$2.2 Billion
Q1 2024

A detailed history of Shell Asset Management CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 85,455 shares of GILD stock, worth $7.53 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

85,455

Previous 90,047 5.1%

Holding current value

$7.53 Million

Previous $6.6 Million 11.11%

% of portfolio

0.27%

Previous 0.29%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 31, 2024	SELL	$71.58 - $87.29 $328,695 - $400,835	-4,592 Reduced 5.1%	85,455 $5.86 Million
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $109,087 - $133,029	1,524 Added 1.72%	90,047 $6.6 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $1.47 Million - $1.66 Million	-20,006 Reduced 18.43%	88,523 $7.17 Million
Q3 2023 Nov 08, 2023	SELL	$73.94 - $80.67 $94,051 - $102,612	-1,272 Reduced 1.16%	108,529 $8.13 Million
Q2 2023 Jul 28, 2023	BUY	$76.01 - $86.7 $1.03 Million - $1.18 Million	13,585 Added 14.12%	109,801 $8.46 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $13,915 - $15,854	180 Added 0.19%	96,216 $7.98 Million
Q4 2022 Feb 07, 2023	BUY	$62.32 - $89.47 $1.22 Million - $1.75 Million	19,551 Added 25.56%	96,036 $8.25 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $913,819 - $1.04 Million	-15,348 Reduced 16.71%	76,485 $4.72 Million
Q2 2022 Aug 09, 2022	SELL	$57.72 - $65.01 $871,110 - $981,130	-15,092 Reduced 14.11%	91,833 $5.68 Million
Q1 2022 May 04, 2022	BUY	$57.92 - $72.58 $5,386 - $6,749	93 Added 0.09%	106,925 $6.36 Million
Q4 2021 Feb 09, 2022	SELL	$64.88 - $73.64 $3.78 Million - $4.29 Million	-58,249 Reduced 35.29%	106,832 $7.76 Million
Q3 2021 Nov 04, 2021	SELL	$67.69 - $73.03 $6.77 Million - $7.3 Million	-100,009 Reduced 37.73%	165,081 $11.5 Million
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $910,667 - $995,033	-14,348 Reduced 5.13%	265,090 $18.3 Million
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $2.49 Million - $2.84 Million	-41,476 Reduced 12.92%	279,438 $18.1 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $5 Million - $5.7 Million	88,348 Added 37.99%	320,914 $18.7 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $255,789 - $321,611	-4,119 Reduced 1.74%	232,566 $14.7 Million
Q2 2020 Aug 10, 2020	BUY	$72.34 - $84.0 $7.45 Million - $8.65 Million	102,929 Added 76.95%	236,685 $18.2 Million
Q1 2020 May 11, 2020	SELL	$62.63 - $80.22 $996,631 - $1.28 Million	-15,913 Reduced 10.63%	133,756 $10 Million
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $4.36 Million - $4.8 Million	70,810 Added 89.79%	149,669 $9.73 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $687 - $759	-11 Reduced 0.01%	78,859 $5 Million
Q2 2019 Aug 12, 2019	SELL	$61.87 - $69.38 $303,967 - $340,863	-4,913 Reduced 5.86%	78,870 $5.33 Million
Q1 2019 May 09, 2019	BUY	$62.53 - $70.05 $48,648 - $54,498	778 Added 0.94%	83,783 $5.45 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $699,479 - $912,766	-11,554 Reduced 12.22%	83,005 $5.19 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $361,532 - $400,282	-5,072 Reduced 5.09%	94,559 $7.3 Million
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $1.59 Million - $1.85 Million	-24,438 Reduced 19.7%	99,631 $7.06 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $273,587 - $333,532	3,756 Added 3.12%	124,069 $9.35 Million
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $1.55 Million - $1.82 Million	21,813 Added 22.15%	120,313 $8.62 Million
Q3 2017 Oct 20, 2017	SELL	$72.11 - $85.47 $12.7 Million - $15 Million	-176,083 Reduced 64.13%	98,500 $7.98 Million
Q3 2017 Oct 18, 2017	BUY	$72.11 - $85.47 $19.8 Million - $23.5 Million	274,583	274,583 $29.2 Million

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Gilead Sciences, Inc. Transaction History